Q-omics provides the consensus-scored ENPP7 profile across patient tissues and cancer cell-line models. ENPP7 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ENPP7 is differentially expressed in 9, with the highest sampling consensus in KIRP. Additionally, ENPP7 RNA expression shows 10,559 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KIRP, and TGCT as cancer lineages where ENPP7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ENPP7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ENPP7 survival associations across molecular data types. ENPP7 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ENPP7 RNA expression–survival associations across cancer types. High ENPP7 expression shows unfavorable associations in ACC, but favorable associations in KIRC, SKCM, UCEC, BLCA and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ENPP7 RNA expression.
This table summarizes ENPP7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for ENPP7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ENPP7 shows lower tumor expression in KIRP, KICH, LUSC and CHOL and higher tumor expression in BRCA and HNSC. The KIRP box plot shows higher ENPP7 RNA expression in normal versus tumor tissue (log2 FC = −1.954, t-test p < 0.001).
This table shows molecular features associated with ENPP7 in patient tissues and cancer cell lines. In patient samples, ENPP7 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ENPP7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LARGE_INTESTINE.
